<DOC>
	<DOCNO>NCT00005975</DOCNO>
	<brief_summary>RATIONALE : Megestrol may effective treat hot flash follow treatment breast cancer . It yet know regimen megestrol effective hot flash . PURPOSE : Randomized phase III trial compare effectiveness different dos megestrol treat hot flash patient undergone therapy breast cancer .</brief_summary>
	<brief_title>S9626 : Megestrol Treating Hot Flashes Following Treatment Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effectiveness duration benefit placebo versus low dose megestrol versus high dose megestrol reduction severe and/or frequent hot flash patient previously treat invasive breast cancer . II . Document effect various dose level megestrol atrophic vaginitis dyspareunia patient . III . Evaluate toxicity treatment patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord tamoxifen use ( yes v ) , number hot flash per week ( 5-34 v 35-63 v 63 ) , duration hot flash ( 6 month less vs longer 6 month ) . Patients randomize one three treatment arm . Arm I : Patients receive oral placebo daily . Arm II : Patients receive low dose oral megestrol daily . Arm III : Patients receive high dose oral megestrol daily . Patients respond 3 month treatment receive additional dose oral megestrol daily . Treatment continue total 6 month absence disease progression unacceptable toxicity . Patients follow 3 month . PROJECTED ACCRUAL : A total 279 eligible patient ( 93 per arm ) expect accrue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis infiltrate breast cancer ( T13 , N01 , M0 ) treat appropriate local regional therapy Chemotherapy and/or surgery complete At least 10 hot flash per week OR At least 5 severe severe hot flash per week No prior participation NCI sponsor breast cancer adjuvant protocol No recurrent persistent vaginal bleeding If postmenopausal vaginal bleeding within past year , must normal endometrial biopsy Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Pre postmenopausal Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No history deep vein thrombosis Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow At least 6 month since prior megestrol At least 1 week since prior nonestrogen contain steroid hormone ( except tamoxifen ) Concurrent tamoxifen allow begin least 4 month prior study No concurrent nonestrogen contain steroid hormone No concurrent estrogen hormone replacement therapy Radiotherapy : Concurrent radiotherapy allow Surgery : See Disease Characteristics Prior hysterectomy allow No concurrent surgery Other : Concurrent nonhormonal prescription nonprescription medication hot flash allow ( e.g. , clonidine , ergotamine tartrate , vitamin E , soy )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>hot flash</keyword>
</DOC>